White Paper

Challenges In Medication Development For Addictions

pills

Addictions are common, debilitating and costly disorders resulting in more than $740 billion a year in increased healthcare costs, crime, and lost productivity.1 Multiple medications have been studied for the treatment of addictions, but only a few have been shown to be efficacious in well-controlled studies. To date, medications that have been approved by the U.S. Food and Drug Administration (FDA) target opioid, alcohol, and nicotine addiction, while no approved medications are available for cocaine, benzodiazepine, and other addictions. Further, even when an approved medication is available for treatment, only a fraction of patients receive medication-assisted therapies.

In this white paper, we present an overview of the medications that have been developed for addictive disorders, the study endpoints that have been used for market approval, and the challenges companies may face when developing medications for addictive disorders.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: